CinDome Pharma Announces First Patient Dosed in the envisionGI Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
CinDome announces that the first participant has been dosed in the envisionGI Phase 2 clinical trial of deudomperidone (CIN-102) in adults with idiopathic gastroparesis.
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma Announces $40 Million Series B Extension